L'Oreal Luxe's 10.5% like-for-like growth in fiscal 2017 substantially overshadowed the 2.2% LFL improvement in the firm's Consumer Products unit. "Maybe in the mass [channel] in the U.S. for the past two or three years, we didn't give consumers enough desire to want to buy beauty," but the company is committed to accelerating innovation and bringing consumers back, CEO Jean-Paul Agon says .
L'Oreal S.A. continues to benefit from robust luxury growth while its mass business proceeds at a relative crawl, trends that may not only reflect the macro factors observed by the firm's peers.
"Beauty is not a consumer goods business. Beauty is different. Beauty is about desire, appetite, excitement. You don't buy beauty...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
CEO Sue Nabi says Coty has created a “multi-functional, stand-alone organization” within its Consumer Beauty business to drive rapid-fire innovation. In a 20 August presentation, Nabi said the firm’s innovation pipeline undergirds its fiscal 2025 outlook of 6%-8% growth.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
